Progyny (NASDAQ:PGNY) Stock Bumped Up to Strong-Buy by Wall Street Zen

Wall Street Zen upgraded shares of Progyny (NASDAQ:PGNY) from a buy rating to a strong-buy rating in a research report report published on Sunday,Wall Street Zen reports.

PGNY has been the subject of several other research reports. Cantor Fitzgerald upped their target price on shares of Progyny from $31.00 to $35.00 and gave the stock an “overweight” rating in a research note on Thursday. Barclays lowered their target price on shares of Progyny from $34.00 to $30.00 and set an “equal weight” rating for the company in a report on Wednesday, August 12th. Weiss Ratings raised shares of Progyny from a “hold (c)” rating to a “hold (c+)” rating in a research report on Thursday, October 8th. BTIG Research boosted their price target on shares of Progyny from $30.00 to $40.00 and gave the stock a “buy” rating in a report on Friday, July 24th. Finally, KeyCorp upped their price objective on shares of Progyny from $30.00 to $35.00 and gave the stock an “overweight” rating in a research report on Monday, July 13th. Eleven analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $34.92.

Progyny Price Performance

PGNY opened at $34.84 on Friday. Progyny has a fifty-two week low of $16.10 and a fifty-two week high of $35.50. The firm has a market capitalization of $2.67 billion, a PE ratio of 31.96, a P/E/G ratio of 1.83 and a beta of 0.97. The company’s 50-day moving average is $27.45 and its 200 day moving average is $24.59.

Progyny (NASDAQ:PGNY) last posted its earnings results on Wednesday, November 4th. The company reported $0.52 earnings per share for the quarter, beating analysts’ consensus estimates of $0.31 by $0.21. Progyny had a return on equity of 19.82% and a net margin of 6.80%. The company had revenue of $341.25 million for the quarter, compared to analyst estimates of $340.76 million. During the same quarter last year, the company earned $0.15 earnings per share. The company’s revenue for the quarter was up 8.9% on a year-over-year basis. As a group, analysts expect that Progyny will post 1.25 EPS for the current year.

Insider Buying and Selling at Progyny

In other news, COO Melissa Cummings sold 1,879 shares of the business’s stock in a transaction that occurred on Wednesday, October 14th. The shares were sold at an average price of $28.00, for a total value of $52,612.00. Following the sale, the chief operating officer owned 66,496 shares of the company’s stock, valued at $1,861,888. The trade was a 2.75% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Allison Swartz sold 3,903 shares of the business’s stock in a transaction that occurred on Wednesday, September 23rd. The shares were sold at an average price of $26.10, for a total transaction of $101,868.30. Following the completion of the sale, the executive vice president directly owned 75,816 shares in the company, valued at approximately $1,978,797.60. This trade represents a 4.90% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 19,421 shares of company stock worth $539,960 over the last three months. Company insiders own 9.90% of the company’s stock.

Institutional Investors Weigh In On Progyny

A number of hedge funds and other institutional investors have recently bought and sold shares of PGNY. Public Employees Retirement System of Ohio purchased a new position in Progyny during the second quarter valued at approximately $29,000. Nykredit A S bought a new stake in Progyny during the 2nd quarter worth approximately $38,000. IFP Advisors Inc increased its holdings in Progyny by 376.0% during the 2nd quarter. IFP Advisors Inc now owns 1,961 shares of the company’s stock worth $57,000 after acquiring an additional 1,549 shares during the period. Toth Financial Advisory Corp purchased a new stake in Progyny in the 2nd quarter worth approximately $65,000. Finally, Integrated Wealth Concepts LLC purchased a new stake in Progyny in the 2nd quarter worth approximately $74,000. Institutional investors own 94.93% of the company’s stock.

Key Headlines Impacting Progyny

Here are the key news stories impacting Progyny this week:

• Positive Sentiment: Progyny reported third-quarter earnings of $0.52 per share and revenue of $341.25 million, slightly above the cited consensus revenue estimate. Revenue grew 8.9% year over year, while earnings increased from $0.15 per share a year earlier. Read More.
• Positive Sentiment: The company raised its full-year 2026 earnings guidance, a sign that management sees stronger earnings prospects. Read More.
• Positive Sentiment: Several analysts raised their price targets following the results: Citizens JMP and Leerink Partners moved to $38, while Cantor Fitzgerald raised its target to $35 and maintained an overweight rating. These revisions reinforce a favorable analyst view, although the targets imply varying degrees of potential upside. Read More.
• Neutral Sentiment: Coverage highlighted new client wins and margin expansion, but also noted a cautious market response. This suggests investors may be weighing growth and profitability improvements against expectations already reflected in the stock. Read More.

Progyny Company Profile

Progyny, Inc is a benefits-management company focused on fertility and family-building care. The company works with employers to provide comprehensive benefits that help members access fertility treatments and related services through a network of specialized providers.

Its offerings include coverage and support for services such as in vitro fertilization, fertility testing, egg and sperm freezing, donor services, gestational surrogacy, and adoption. Progyny also provides pharmacy benefits through Progyny Rx, as well as personalized guidance intended to help members navigate treatment options, providers, and the broader family-building process.

Progyny primarily serves self-insured employers and their employees in the United States.